With this key development, Kraig Labs is accelerating its production growth, positioning the Company to execute its ambitious ...

The Phase 1 trial of PLN-101095 is currently enrolling the fourth of five potential cohorts. The fourth cohort is evaluating ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia. First-in-class Bruton’s tyrosine kinase (BT ...

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody ® Pipeline and Platform ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic cardiomyopathy (HCM), at the American ...

The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award!

The Company granted stock options to purchase up to an aggregate of 34,500 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on March 14, 2025. The ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat ...

The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...

Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, ...

Celex Oncology’s first attendance at Bio-Europe Spring 2025 follows their recent win at the 2024 EIT Health Catapult ...

The CTA approval is the first regulatory authorisation in Europe to study a non-viral gene-edited TCR-T therapy in clinical practice, paving the way for the execution of Anocca’s scalable clinical ...